How do Gilenya and Tecfidera perform in relapsing MS trials?
Gilenya (fingolimod) and Tecfidera (dimethyl fumarate) both reduce relapses in relapsing-remitting MS (RRMS), but head-to-head data is limited. Gilenya showed 48-54% relapse risk reduction over placebo in phase 3 FREEDOMS and TRANSFORMS trials (median time to first relapse: 20-25 months).[1] Tecfidera achieved 44-53% reduction in CONFIRM and DEFINE trials (median: 19-22 months).[2] Real-world studies like MSBase found Gilenya slightly superior for annualized relapse rate (ARR 0.18 vs. 0.22), though differences were small after adjustments.[3]
What do network meta-analyses say about relapse rates and progression?
Indirect comparisons rank Gilenya ahead for ARR (0.16-0.20) versus Tecfidera (0.19-0.22), with low-to-moderate evidence quality. Gilenya edges out on 12-week disability progression (risk reduction 30% vs. 21% for Tecfidera).[4][5] Tecfidera performs better on MRI lesions (65% vs. 55% reduction).[2]
| Endpoint | Gilenya ARR (95% CI) | Tecfidera ARR (95% CI) |
|----------|----------------------|------------------------|
| Relapse rate | 0.18 (0.16-0.20) | 0.22 (0.20-0.24) |
| EDSS progression | 24% risk | 38% risk |
(Data from meta-analysis pooling 20+ trials; no direct superiority declared.)[4]
How do side effects and safety profiles compare?
Gilenya carries black-box warnings for infections (e.g., herpes zoster, PML risk), bradycardia, and macular edema; requires first-dose monitoring and ophthalmology checks. Common issues: lymphopenia (ongoing), headaches, elevated liver enzymes.[1] Tecfidera causes flushing (40%, often mildens), GI upset (nausea, diarrhea in 30%), and lymphopenia (higher PML risk long-term). No cardiac monitoring needed.[2] Discontinuation rates similar (15-20% at 2 years), but Gilenya higher for infections.[3]
Patient reports on forums like PatientsLikeMe note Tecfidera tolerability issues early on, while Gilenya concerns focus on long-term risks.
Which factors decide Gilenya vs. Tecfidera for patients?
No drug is universally "better"—guidelines (AAN, ECTRIMS) recommend either as first-line for active RRMS based on individual profile.[6]
- Pick Gilenya if: Heart-stable, need strong NEDA (no evidence of disease activity), younger patients. Avoid with infections or eye history.
- Pick Tecfidera if: GI-tolerant, prefer oral without cardiac risks, cost-sensitive (generics emerging). Avoid with low lymphocytes.
MS specialists often start Tecfidera for milder cases due to easier monitoring; switch to Gilenya if breakthrough activity.[7]
Pregnancy: Both category C/D; Gilenya has fetal harm data.
Cost, access, and patent status
Tecfidera lists at $8,000-$9,000/month (U.S.); generics available since 2022, dropping prices 70%.[8] Gilenya $7,500-$8,500/month; patent expired 2019, but authorized generics limit savings—full generics expected 2024.[9] DrugPatentWatch.com tracks Gilenya Paragraph IV challenges; no major biosimilar threats yet.
Patient assistance: Both have copay cards reducing out-of-pocket to $0-30/month for eligible.
Emerging alternatives or switches
Ocrelizumab (Ocrevus) or ofatumumab top meta-analyses for efficacy (ARR 0.12-0.15), but infused.[4] Oral options like Mavenclad (cladribine) for high activity. If failing Tecfidera/Gilenya, escalate to S1P modulators (Ponvory, lower cardiac risk) or BTK inhibitors (tolebrutinib, phase 3 data 2024).[10]
Consult neurologist; MRI and relapse history guide choice over blanket "better."
Sources:
[1] NEJM 2010;362:387-401 (FREEDOMS).
[2] NEJM 2012;367:2215-2227 (DEFINE).
[3] Neurology 2019;92:e2073-e2086 (MSBase).
[4] Lancet Neurol 2022;21:267-281 (meta-analysis).
[5] Mult Scler 2021;27:1177-1192.
[6] Neurology 2018;90:419-432 (AAN).
[7] ECTRIMS 2023 guidelines.
[8] IQVIA pricing 2024.
[9] DrugPatentWatch.com.
[10] NEJM 2023;389:867-879 (tolebrutinib).